Study of a targeted drug with immunotherapy and chemo for advanced stomach cancer
Part of Cancer, Digestive system clinical trials.
This study tests a new combination of three drugs (disitamab vedotin, tislelizumab, and chemotherapy) compared to two of them (tislelizumab plus chemotherapy) for people with advanced stomach or gastroesophageal junction cancer that has low levels of a protein called HER2. It aims to see if adding the third drug helps shrink or control the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stomach or gastroesophageal junction adenocarcinoma (a type of cancer) that is either advanced, has spread to other parts of the body, or has come back and cannot be removed with surgery.
- You have not had any previous systemic treatment (like chemotherapy given through the body) for this advanced stage.
- Your cancer must be HER2-low, meaning it has a low amount of a specific protein on its surface.
- You need to be generally active and able to take care of yourself (able to work but not do heavy physical tasks).
- You must be willing to use birth control during the study and for 6 months after treatment ends (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (Disitamab Vedotin, Trastuzumab, and Tislelizumab) against standard chemotherapy plus Trastuzumab (with or without Pembrolizumab) for people with advanced or metastatic stomach or gastroesophageal junction cancer that has high levels of HER2. The goal is to see if the new combination works better.
This trial tests a combination of three drugs (targeted therapy, immunotherapy, and chemotherapy) before and after surgery for locally advanced HER2-positive stomach cancer. It aims to see if this treatment can improve outcomes for patients whose cancer has not yet spread.
This trial tests a combination of three drugs (Disitamab Vedotin, Toripalimab, and XELOX) given before and after surgery for gastric or gastroesophageal junction cancer. The goal is to see if this treatment helps shrink the tumor and prevent it from coming back.
This trial tests a new combination of two drugs for stomach cancer that has spread and shows a specific protein (HER2). The goal is to see if the combination helps patients who haven't had treatment for advanced disease.
This trial tests a combination of two targeted drugs (disitamab vedotin and sintilimab) along with radiation for HER2-positive stomach cancer that has stopped responding to standard treatments. The goal is to see if this combo can shrink tumors and help you live longer.
This trial tests a new combination of drugs (RC48, sintilimab, and SOX chemotherapy) for people with stomach or gastroesophageal junction cancer that cannot be removed by surgery, has not been treated before, and has a specific HER2 score (1+ or 2+). The goal is to shrink the tumor enough to possibly allow surgical removal.
Hear when a new Gastric Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.